Accessibility Menu
Tourmaline Bio logo

Tourmaline Bio(NASDAQ) TRML

This security has been delisted. This page is retained for historical reference.

Tourmaline Bio last closing stock price
MetricPriceDate
Last closeUSD 47.982025-10-27
Tourmaline Bio stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0.1%USD 47.932025-10-20
1 month+0.5%USD 47.742025-09-26
3 month+111.46%USD 22.692025-07-29
Year to date+136.59%USD 20.282024-12-31
1 year+80.44%USD 26.592024-10-25
3 year+579.35%USD 7.062022-10-28
Since inception+340.18%USD 10.902023-10-20

TRML News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

TRML Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-17.09%

Return on Capital

-29.88%

Return on Assets

-17.10%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

-$14.00K

Operating Income

-$102.45M

EBITDA

-$95.59M

Operating Cash Flow

-$86.28M

Capital Expenditure

-$25.00K

Free Cash Flow

-$86.30M

Cash & ST Invst.

$239.23M

Total Debt

$145.00K

Tourmaline Bio Performance Analysis

Tourmaline Bio annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20212021-12-31USD 0N/A
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
Tourmaline Bio sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32024-09-30N/A
Q42024-12-31N/A
Q12025-03-31-100.0%
Q22025-06-30N/A
Tourmaline Bio annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20212021-12-31USD -16.42N/A
20222022-12-31USD -22.4636.8%
20232023-12-31USD -8.87-60.5%
20242024-12-31USD -2.89-67.5%
Tourmaline Bio sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32024-09-30-14.7%
Q42024-12-31-10.3%
Q12025-03-31-3.5%
Q22025-06-30-1.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2025YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$12.00K

-20.0%

Gross Margin

0.00%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

74

N/A

Net Income

-$23.09M

-32.1%

EBITDA

-$25.97M

-18.3%

Quarterly Fundamentals

Name
Q2 2025YOY CHG

Total Cash

$239.23M

-17.4%

Total Debt

$145.00K

-56.5%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

-100.0%

Short Term Debt

$145.00K

-35.3%

Return on Assets

-17.10%

N/A

Return on Invested Capital

-20.14%

N/A

Free Cash Flow

-$20.27M

-12.6%

Operating Cash Flow

-$20.26M

-12.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
TERNTerns Pharmaceuticals, Inc.
$52.95-0.03%
PGENPrecigen, Inc.
$6.55+7.38%
IMTXImmatics N.V.
$9.25-2.01%
ORICORIC Pharmaceuticals, Inc.
$13.38-3.53%

Trending Stocks

Symbol / CompanyPricePrice Chg
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$38.36-0.05%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$151.53+0.05%
TQQQProShares Trust - ProShares UltraPro Qqq
$76.40-0.01%
NOKNokia
$10.78+0.00%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.